Published in Qual Saf Health Care on April 01, 2007
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy (2012) 2.49
Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res (2011) 1.04
The volume-outcome relationship in laparoscopic cholecystectomy: a population-based study using propensity score matching. Surg Endosc (2013) 0.80
Costs of venous thromboembolism associated with hospitalization for medical illness. Am J Manag Care (2015) 0.80
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Estimating log models: to transform or not to transform? J Health Econ (2001) 11.10
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 4.03
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med (2001) 3.85
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet (2006) 2.92
Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison. Am Heart J (1999) 2.72
Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy (2004) 2.59
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 2.27
Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol (2003) 2.18
Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol (2000) 2.12
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med (1999) 1.55
Continuous quality improvement decreases length of stay and adverse events: a case study in an interventional cardiology program. Am J Manag Care (1997) 1.41
Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med (1997) 1.38
Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol (2002) 1.29
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA (2001) 1.22
Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials. Appl Health Econ Health Policy (2005) 1.09
Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol (1993) 0.97
The Northern New England Cardiovascular Disease Study Group: a regional collaborative effort for continuous quality improvement in cardiovascular disease. Jt Comm J Qual Improv (1998) 0.92
Hospital resources consumed in treating complications associated with percutaneous coronary interventions. Am J Cardiol (2006) 0.89
Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol (2002) 0.87
Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J (2004) 0.86
Predictors of length of stay after coronary stenting. Am Heart J (2001) 0.86
Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol (2001) 0.86
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol (2005) 0.85
Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc (2001) 0.84
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol (2005) 0.84
Clinical pathways--an evaluation of its impact on the quality of care in an acute care general hospital in Singapore. Singapore Med J (2000) 0.84
Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories. Am J Cardiol (2000) 0.82
Percutaneous transluminal coronary angioplasty: current status and future trends. Mayo Clin Proc (1986) 0.81
Reducing costs and improving outcomes of percutaneous coronary interventions. Am J Manag Care (2003) 0.81
Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol (1994) 0.80
Competitive bidding for interventional cardiology supplies: lessons learned during round 2. Am J Manag Care (2002) 0.79
Evaluating and improving the delivery of heart care: the University of Michigan experience. Am J Manag Care (1998) 0.77
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol (1999) 0.77
Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol (2006) 0.76
Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med (2004) 11.40
Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J (2008) 9.50
A randomized controlled trial of telemonitoring in older adults with multiple health issues to prevent hospitalizations and emergency department visits. Arch Intern Med (2012) 5.00
Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation (2012) 4.13
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29
Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial. Ann Intern Med (2004) 3.21
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol (2004) 3.19
Cardiac shunt calculations made easy: a case-based approach. Catheter Cardiovasc Interv (2010) 2.69
Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv (2011) 2.63
The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension (2008) 2.56
Myocardial bridging. Eur Heart J (2005) 2.56
Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol (2007) 2.53
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol (2005) 2.51
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Risk-stratification methods for identifying patients for care coordination. Am J Manag Care (2013) 2.40
A program of anticipatory guidance for the prevention of emergency department visits for ear pain. Arch Pediatr Adolesc Med (2008) 2.36
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
Evaluating the performance of an institution using an intensive care unit benchmark. Mayo Clin Proc (2005) 2.13
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol (2005) 2.00
Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv (2002) 1.98
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (2007) 1.91
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation (2007) 1.89
Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol (2009) 1.87
Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty. J Am Coll Cardiol (2004) 1.82
Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J (2012) 1.80
Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv (2011) 1.80
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J (2013) 1.76
Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): clinical correlates and Mayo Clinic risk score. J Am Coll Cardiol (2011) 1.74
Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol (2003) 1.74
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol (2007) 1.68
Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol (2009) 1.67
Ambulation 1 hour after diagnostic cardiac catheterization: a prospective study of 1009 procedures. Mayo Clin Proc (2006) 1.67
Diagnosis and treatment of viral myocarditis. Mayo Clin Proc (2009) 1.65
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Successful percutaneous repair of perivalvular prosthetic regurgitation. Catheter Cardiovasc Interv (2007) 1.60
Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ Cardiovasc Interv (2011) 1.58
Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J (2009) 1.58
Economic implications of nighttime attending intensivist coverage in a medical intensive care unit. Crit Care Med (2011) 1.57
Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J (2008) 1.53
Complications associated with left ventricular puncture. Catheter Cardiovasc Interv (2010) 1.52
Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA (2011) 1.51
Safety of same-day coronary angiography in patients undergoing elective aortic valve replacement. Ann Thorac Surg (2011) 1.51
Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv (2012) 1.51
Transient cardiac apical ballooning syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol (2006) 1.51
Web-based proactive system to improve breast cancer screening: a randomized controlled trial. Arch Intern Med (2007) 1.50
Location of femoral artery access and correlation with vascular complications. Catheter Cardiovasc Interv (2011) 1.50
Subepicardial adipose tissue and the presence and severity of coronary artery disease. Atherosclerosis (2005) 1.50
Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol (2007) 1.49
Hydrophilic polymer embolism induced acute transcatheter aortic valve thrombosis: a novel complication. Catheter Cardiovasc Interv (2014) 1.47
Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv (2010) 1.47
Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J (2004) 1.47
Myocardial bridging is associated with alteration in coronary vasoreactivity. Eur Heart J (2004) 1.47
Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol (2011) 1.47
Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol (2006) 1.46
Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv (2008) 1.45
All at-risk patients are not created equal: analysis of Braden pressure ulcer risk scores to identify specific risks. J Wound Ostomy Continence Nurs (2012) 1.45
Economic and clinical outcomes of a physician-led continuous quality improvement intervention in the delivery of percutaneous coronary intervention. Am J Manag Care (2006) 1.42
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J (2003) 1.41
Effect of discharge instructions on readmission of hospitalised patients with heart failure: do all of the Joint Commission on Accreditation of Healthcare Organizations heart failure core measures reflect better care? Qual Saf Health Care (2006) 1.41
Neuroimaging patterns of ischemic stroke after percutaneous coronary intervention. Catheter Cardiovasc Interv (2014) 1.40
Sustaining improvement in door-to-balloon time over 4 years: the Mayo clinic ST-elevation myocardial infarction protocol. Circ Cardiovasc Qual Outcomes (2009) 1.40
Recollection of previous colon cancer screening in Minnesota adults. Minn Med (2005) 1.40
Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury. Am Heart J (2006) 1.39
Transcatheter aortic valve insertion catastrophe in inoperable patients: should aortic valve replacement be denied? J Card Surg (2013) 1.39
Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc (2008) 1.38
Minimally invasive transradial intervention using sheathless standard guiding catheters. Catheter Cardiovasc Interv (2011) 1.38
Magnetic navigation facilitates percutaneous coronary intervention for complex lesions. Catheter Cardiovasc Interv (2013) 1.38
Percutaneous coronary intervention in native vessels with angiographically visible thrombus temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv (2010) 1.38
Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. JACC Cardiovasc Interv (2012) 1.35
Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation (2007) 1.33
Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. Circ Cardiovasc Qual Outcomes (2011) 1.32
Percutaneous closure of congenital coronary artery fistulae: results and angiographic follow-up. JACC Cardiovasc Interv (2011) 1.32
Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol (2002) 1.29
Complications of endovascular polymers associated with vascular introducer sheaths and metallic coils in 3 patients, with literature review. Am J Surg Pathol (2008) 1.26
A randomized trial of three diabetes registry implementation strategies in a community internal medicine practice. Jt Comm J Qual Improv (2002) 1.24
Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohort. Med Care (2008) 1.24
Effect of weekend hospital admission on gastrointestinal hemorrhage outcomes. Dig Dis Sci (2009) 1.22
Coronary revascularization in the community. A population-based study, 1990 to 2004. J Am Coll Cardiol (2007) 1.21
Current status of endomyocardial biopsy. Mayo Clin Proc (2011) 1.20
Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol (2008) 1.20
Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc (2007) 1.19
Predictors of discharge to an inpatient extended care facility after total hip or knee arthroplasty. J Arthroplasty (2006) 1.19
Effect of hospital follow-up appointment on clinical event outcomes and mortality. Arch Intern Med (2010) 1.18
Determinants of direct medical costs in primary and revision total knee arthroplasty. Clin Orthop Relat Res (2013) 1.16
A collaborative of leading health systems finds wide variations in total knee replacement delivery and takes steps to improve value. Health Aff (Millwood) (2012) 1.14